Myriad Signs Contract with UnitedHealthcare for MyRisk Hereditary Cancer Risk Panel | GenomeWeb

NEW YORK (GenomeWeb) – Myriad Genetics has signed a three-year contract with national payor UnitedHealthcare to provide access to its next-generation sequencing myRisk Hereditary Cancer test to beneficiaries who meet certain eligibility criteria for hereditary cancer risk.

The myRisk test gauges 25 genes associated with eight hereditary cancers, including breast, colon, ovarian, endometrial, pancreatic, prostate, and gastric cancers, and melanoma.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.